No image
Methotrexate 25 mg/1 mL Sub-C
Product Overview
| Generic Name | Methotrexate 25 mg/1 mL Sub-C |
| Brand Name(s) | Rheumatrex, Trexall |
| Category | Antineoplastic / Cancer |
| Form | Inj Vial, Sub-C |
| Strength | 25 mg/1 mL |
| Therapeutic Class | Dihydrofolate reductase inhibitor |
| ATC Code | L01BA01 |
Manufacturing & Regulatory
| Manufacturer | Actiza, Actavis, Teva |
| GMP Compliance | WHO-GMP certified |
| DMF/CEP | Type II |
| COFEPRIS | Batch-specific |
| Free Sale Certificate | Yes |
Logistics & Export
| MOQ | 10 packs |
| Shelf Life | 24 Months |
| Storage | 2–8 °C, protect from light |
| Incoterms | EXW/FOB/CIF negotiable |
| Lead Time | 7 to 10 Days |
Documentation Available Upon Request
| Certificate of Analysis (PDF) | Supplied per batch upon request |
| SDS-Safety Data Sheet (PDF) | Upon Request, not publicly posted |
| CTD Summary (PDF) | CTD from originator; generic use abbreviated formats |
Special Notes
Indications & Usage: Methotrexate is indicated for: • acute lymphoblastic leukemia (ALL) maintenance (20 mg/m² once weekly) • mycosis fungoides; relapsed/refractory non-Hodgkin lymphoma (metronomic) • rheumatoid arthritis (starting ~7.5 mg once weekly) • polyarticular juvenile idiopathic arthritis (starting 10 mg/m² weekly) • severe psoriasis (initial 10–25 mg once weekly